Jafron Biomedical Co Stock Current Valuation
| 300529 Stock | 30.38 0.29 0.95% |
Valuation analysis of Jafron Biomedical helps investors to measure Jafron Biomedical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Jafron Biomedical's Cash is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 10.8 M, whereas Total Cash From Operating Activities is forecasted to decline to about 518.8 M. Fundamental drivers impacting Jafron Biomedical's valuation include:
Price Book 7.4464 | Enterprise Value 23.4 B | Enterprise Value Ebitda 22.5244 | Price Sales 9.1419 | Trailing PE 29.8317 |
Fairly Valued
Today
Please note that Jafron Biomedical's price fluctuation is not too volatile at this time. Calculation of the real value of Jafron Biomedical is based on 3 months time horizon. Increasing Jafron Biomedical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Jafron Biomedical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jafron Stock. However, Jafron Biomedical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.38 | Real 30.51 | Hype 29.86 | Naive 29.3 |
The real value of Jafron Stock, also known as its intrinsic value, is the underlying worth of Jafron Biomedical Company, which is reflected in its stock price. It is based on Jafron Biomedical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Jafron Biomedical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Jafron Biomedical Co helps investors to forecast how Jafron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jafron Biomedical more accurately as focusing exclusively on Jafron Biomedical's fundamentals will not take into account other important factors: Jafron Biomedical Co Company Current Valuation Analysis
Jafron Biomedical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Jafron Biomedical Current Valuation | 23.4 B |
Most of Jafron Biomedical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jafron Biomedical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Jafron Biomedical Co has a Current Valuation of 23.4 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.
Jafron Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jafron Biomedical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jafron Biomedical could also be used in its relative valuation, which is a method of valuing Jafron Biomedical by comparing valuation metrics of similar companies.Jafron Biomedical is currently under evaluation in current valuation category among its peers.
Jafron Fundamentals
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 23.4 B | ||||
| Shares Outstanding | 798.6 M | ||||
| Shares Owned By Insiders | 51.06 % | ||||
| Shares Owned By Institutions | 13.16 % | ||||
| Price To Book | 7.45 X | ||||
| Price To Sales | 9.14 X | ||||
| Revenue | 1.92 B | ||||
| Gross Profit | 2.27 B | ||||
| EBITDA | 1.04 B | ||||
| Net Income | 436.49 M | ||||
| Total Debt | 261.83 M | ||||
| Book Value Per Share | 4.25 X | ||||
| Cash Flow From Operations | 916.74 M | ||||
| Earnings Per Share | 1.01 X | ||||
| Target Price | 38.21 | ||||
| Number Of Employees | 2.41 K | ||||
| Beta | 0.36 | ||||
| Market Capitalization | 24.06 B | ||||
| Total Asset | 5.54 B | ||||
| Retained Earnings | 2 B | ||||
| Working Capital | 2.48 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 5.54 B | ||||
| Last Dividend Paid | 0.4 |
About Jafron Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jafron Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jafron Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jafron Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Jafron Stock
Jafron Biomedical financial ratios help investors to determine whether Jafron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jafron with respect to the benefits of owning Jafron Biomedical security.